LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for Prostate cancer: Side Effects & Safety Data
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
There are 421 adverse event reports in the FDA FAERS database where LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN was used for Prostate cancer.
Most Reported Side Effects for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| General physical health deterioration | 4,332 | 40.4% | 93 | 125 |
| Ill-defined disorder | 3,600 | 33.6% | 129 | 111 |
| Death | 1,179 | 11.0% | 1,179 | 30 |
| Disease progression | 286 | 2.7% | 36 | 18 |
| Malignant neoplasm progression | 251 | 2.3% | 81 | 47 |
| Laboratory test abnormal | 233 | 2.2% | 11 | 9 |
| Prostatic specific antigen increased | 212 | 2.0% | 20 | 19 |
| Fatigue | 177 | 1.7% | 18 | 24 |
| Anaemia | 154 | 1.4% | 28 | 62 |
| Covid-19 | 139 | 1.3% | 8 | 5 |
| Platelet count decreased | 130 | 1.2% | 18 | 14 |
| Illness | 124 | 1.2% | 9 | 16 |
| Drug ineffective | 114 | 1.1% | 9 | 7 |
| Thrombocytopenia | 113 | 1.1% | 31 | 39 |
| Hormone-refractory prostate cancer | 110 | 1.0% | 40 | 19 |
Other Indications for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Product used for unknown indication (9,348)
Hormone-refractory prostate cancer (579)
Prostate cancer metastatic (314)
Hormone-dependent prostate cancer (32)
Neoplasm malignant (18)
Bone cancer (10)
Metastases to bone (10)
Genitourinary melanoma (5)
Other Drugs Used for Prostate cancer
LEUPROLIDE (45,399)
ENZALUTAMIDE (25,954)
RELUGOLIX (18,752)
ABIRATERONE (12,209)
APALUTAMIDE (3,286)
GOSERELIN (2,080)
DEGARELIX (2,035)
BICALUTAMIDE (1,832)
SIPULEUCEL-T (1,720)
DENOSUMAB (1,627)